<i>Ex Vivo</i> and <i>In Vivo</i> CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26)
Jack R. Hemsath, A. Manuel Liaci, Jeffrey D. Rubin, Brian J. Parrett, Shao‐Chia Lu, Tien Anh Nguyen, Mallory A. Turner, Christopher Y. Chen, Karolina Cupelli, Vijay Reddy, Thilo Stehle, M. Kathryn Liszewski, John P. Atkinson, Michael A. Barry
Abstract
The human species D Ad26 is being investigated as a low-seroprevalence vector for oncolytic virotherapy and gene-based vaccination against HIV-1 and SARS-CoV-2. However, there is debate in the literature about its tropism and receptor utilization, which directly influence its efficiency for certain applications. This work was aimed at determining which receptor(s) this virus uses for infection and its role in virus biology, vaccine efficacy, and, importantly, vaccine safety.
Topics & Concepts
BiologyGenetic enhancementCD46AdenoviridaeImmunologyMolecular biologyImmune systemComplement systemGeneticsGeneVirus-based gene therapy researchCAR-T cell therapy researchHerpesvirus Infections and Treatments